Conference
507P A phase 1 study evaluating the pharmacokinetics (PK) and safety of regorafenib (REG) in patients with advanced solid tumors with severe renal impairment (SRI)
Authors
Renouf DJ; Hirte HW; O'Bryant CL; Trnkova ZJ; Cleton A; Huang F; Mueller U; Ayoub J-P; Lockhart AC; Quinn DI
Volume
27
Publisher
Elsevier
Publication Date
October 1, 2016
DOI
10.1093/annonc/mdw370.55
Conference proceedings
Annals of Oncology
ISSN
0923-7534